4-{5-[3-(3-phenyl-prop-1-ynyl)-phenyl]-[1,3,4]oxadiazol-2-ylmethyl}-benzoic acid | 660859-34-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮
• 英文名称: 4-{5-[3-(3-phenyl-prop-1-ynyl)-phenyl]-[1,3,4]oxadiazol-2-ylmethyl}-benzoic acid
• 英文别名: 4-[[5-[3-(3-Phenylprop-1-ynyl)phenyl]-1,3,4-oxadiazol-2-yl]methyl]benzoic acid
• CAS: 660859-34-7
• 化学式: C₂₅H₁₈N₂O₃
• 分子量: 394.43
• InChiKey: QQPLVPFQMZHHEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  76.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES HETERO BIARYLE INHIBITEURS DE LA METALLOPROTEASE MATRICIELLE
  申请人：WARNER LAMBERT CO

  公开号：WO2004014366A1

  公开（公告）日：2004-02-19

  This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein Rl, Q, S, T, U, V, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a' pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a' compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency,,inflammatory bowel, disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically, acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active, component as described in the specification.

  该发明提供了由式I定义或其药用盐组成的化合物，其中R1、Q、S、T、U、V和R2如规范中所定义。该发明还提供了包括式I的化合物或其药用盐以及药用载体、稀释剂或赋形剂的药物组合物，如规范中所定义。该发明还提供了在动物体内抑制MMP-13酶的方法，包括向动物体内给予式I的化合物或其药用盐。该发明还提供了治疗患有MMP-13酶介导疾病的患者的方法，包括向患者体内给予式I的化合物或其药用盐，单独或与药物组合使用。该发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、非骨关节炎或类风湿性关节炎的关节炎、心力衰竭、炎性肠病、心力衰竭、年龄相关性黄斑变性、慢性阻塞性肺病、哮喘、牙周疾病、牛皮癣、动脉粥样硬化和骨质疏松症的方法，包括向患者体内给予式I的化合物或其药用盐，单独或与药物组合使用。该发明还提供了组合物，包括式I的化合物或其药用盐，以及规范中描述的另一种药用活性成分。
• Hetero biaryl derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040048863A1

  公开（公告）日：2004-03-11

  This invention provides compounds defined by Formula I 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, S, T, U, V, and R 2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由公式I1定义的化合物或其药学上可接受的盐，其中R1、Q、S、T、U、V和R2如规范中所定义。本发明还提供了包括公式I的化合物或其药学上可接受的盐的制药组合物，以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了抑制动物中MMP-13酶的方法，包括向动物中给予公式I的化合物或其药学上可接受的盐。本发明还提供了治疗由MMP-13酶介导的疾病的方法，包括向患者中给予公式I的化合物或其药学上可接受的盐，单独或与制药组合物一起。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、除骨关节炎和类风湿性关节炎外的其他关节炎、心力衰竭、炎症性肠病、心力衰竭、年龄相关性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周病、银屑病、动脉粥样硬化和骨质疏松症的方法，包括向患者中给予公式I的化合物或其药学上可接受的盐，单独或与制药组合物一起。本发明还提供了包括公式I的化合物或其药学上可接受的盐和规范中描述的另一个药学活性成分的组合物。
• HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Bunker Amy Mae

  公开号：US20090029995A1

  公开（公告）日：2009-01-29

  This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, S, T, U, V, and R 2 are as defined in the specification. The invention also provides pharmaceutical compositions and methods of treating diseases.

  该发明提供了由式I或其药学上可接受的盐定义的化合物，其中R1、Q、S、T、U、V和R2如规范中所定义。该发明还提供了药物组合物和治疗疾病的方法。
• US7179822B2
  申请人：——

  公开号：US7179822B2

  公开（公告）日：2007-02-20